89 related articles for article (PubMed ID: 8914799)
1. Adenovirus for neurodegenerative diseases: in vivo strategies and ex vivo gene therapy using human neural progenitors.
Sabaté O; Barkats M; Buc-Caron MH; Castel-Barthe MN; Finiels F; Horellou P; Revah F; Mallet J
Clin Neurosci; 1995-1996; 3(5):317-21. PubMed ID: 8914799
[TBL] [Abstract][Full Text] [Related]
2. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions.
Snyder EY; Macklis JD
Clin Neurosci; 1995-1996; 3(5):310-6. PubMed ID: 8914798
[TBL] [Abstract][Full Text] [Related]
3. Application of ex vivo gene therapy in the treatment of Parkinson's disease.
Raymon HK; Thode S; Gage FH
Exp Neurol; 1997 Mar; 144(1):82-91. PubMed ID: 9126156
[TBL] [Abstract][Full Text] [Related]
4. In vivo adenovirus-mediated gene transfer for Parkinson's disease.
Horellou P; Bilang-Bleuel A; Mallet J
Neurobiol Dis; 1997; 4(3-4):280-7. PubMed ID: 9361305
[TBL] [Abstract][Full Text] [Related]
5. Transplantation to the rat brain of human neural progenitors that were genetically modified using adenoviruses.
Sabaté O; Horellou P; Vigne E; Colin P; Perricaudet M; Buc-Caron MH; Mallet J
Nat Genet; 1995 Mar; 9(3):256-60. PubMed ID: 7773288
[TBL] [Abstract][Full Text] [Related]
6. A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors.
Corti O; Sabaté O; Horellou P; Colin P; Dumas S; Buchet D; Buc-Caron MH; Mallet J
Nat Biotechnol; 1999 Apr; 17(4):349-54. PubMed ID: 10207882
[TBL] [Abstract][Full Text] [Related]
7. Towards gene therapy in the nervous system.
Doering LC
Clin Neurosci; 1995-1996; 3(5):259-61. PubMed ID: 8914791
[TBL] [Abstract][Full Text] [Related]
8. The change of the neuron-glia differentiation rate in human neural precursor cells (HPCs) and Ad-BDNF-/-GDNF-infected HPCs following the administration of a neurotoxin.
Yoo YM; Kim YJ; Lee U
Neurosci Lett; 2005 Oct; 387(2):100-4. PubMed ID: 16081212
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological, cell, and gene therapy strategies to promote spinal cord regeneration.
Blits B; Boer GJ; Verhaagen J
Cell Transplant; 2002; 11(6):593-613. PubMed ID: 12428749
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease.
Horellou P; Sabaté O; Buc-Caron MH; Mallet J
Exp Neurol; 1997 Mar; 144(1):131-8. PubMed ID: 9126162
[TBL] [Abstract][Full Text] [Related]
11. Development of PEGylated adenovirus vector with targeting ligand.
Eto Y; Yoshioka Y; Mukai Y; Okada N; Nakagawa S
Int J Pharm; 2008 Apr; 354(1-2):3-8. PubMed ID: 17904316
[TBL] [Abstract][Full Text] [Related]
12. Approaches to utilize mesenchymal progenitor cells as cellular vehicles.
Pereboeva L; Komarova S; Mikheeva G; Krasnykh V; Curiel DT
Stem Cells; 2003; 21(4):389-404. PubMed ID: 12832693
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain.
Kojima H; Abiru Y; Sakajiri K; Watabe K; Ohishi N; Takamori M; Hatanaka H; Yagi K
Biochem Biophys Res Commun; 1997 Sep; 238(2):569-73. PubMed ID: 9299553
[TBL] [Abstract][Full Text] [Related]
14. Use of protamine to augment adenovirus-mediated cancer gene therapy.
Lanuti M; Kouri CE; Force S; Chang M; Amin K; Xu K; Blair I; Kaiser L; Albelda S
Gene Ther; 1999 Sep; 6(9):1600-10. PubMed ID: 10490770
[TBL] [Abstract][Full Text] [Related]
15. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.
Bowers WJ; Howard DF; Federoff HJ
Exp Neurol; 1997 Mar; 144(1):58-68. PubMed ID: 9126153
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated GDNF and CNTF pretreatment protects against striatal injury following transient middle cerebral artery occlusion in mice.
Hermann DM; Kilic E; Kügler S; Isenmann S; Bähr M
Neurobiol Dis; 2001 Aug; 8(4):655-66. PubMed ID: 11493030
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
Bauerschmitz GJ; Barker SD; Hemminki A
Int J Oncol; 2002 Dec; 21(6):1161-74. PubMed ID: 12429964
[TBL] [Abstract][Full Text] [Related]
18. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.
Schagen FH; Ossevoort M; Toes RE; Hoeben RC
Crit Rev Oncol Hematol; 2004 Apr; 50(1):51-70. PubMed ID: 15094159
[TBL] [Abstract][Full Text] [Related]
19. High-capacity 'gutless' adenoviral vectors.
Kochanek S; Schiedner G; Volpers C
Curr Opin Mol Ther; 2001 Oct; 3(5):454-63. PubMed ID: 11699889
[TBL] [Abstract][Full Text] [Related]
20. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
